Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Its mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. 

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2010
Size (employees)
135 (est)
Website
sagerx.com
Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, US

Key People at Sage Therapeutics

Jeffrey Jonas

Jeffrey Jonas

Chief Executive Officer
Kimi Iguchi

Kimi Iguchi

CFO
Stephen Kanes

Stephen Kanes

Chief Medical Officer
Albert J. Robichaud

Albert J. Robichaud

CSO
Thomas Anderson

Thomas Anderson

Chief Commercial Strategy Officer
Jim Doherty

Jim Doherty

Vice President of Pharmacology, Head of Biology

Sage Therapeutics Office Locations

Sage Therapeutics has an office in Cambridge
Cambridge, US (HQ)
215 First Street

Sage Therapeutics Data and Metrics

Sage Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(56.8 m)

EBIT (Q1, 2017)

(57.5 m)

Market capitalization (15-Aug-2017)

3.2 b

Cash (31-Mar-2017)

145.5 m
Sage Therapeutics's current market capitalization is $3.2 b.
USDFY, 2014FY, 2015FY, 2016

R&D expense

24.1 m69.4 m120.8 m

General and administrative expense

9.7 m25.3 m39.4 m

Operating expense total

33.8 m94.7 m160.2 m

EBIT

(33.8 m)(94.7 m)(160.2 m)

Interest expense

8 k

Interest income

8 k

Net Income

(33.8 m)(94.5 m)(159 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

12.9 m18.6 m17.5 m23.6 m26.1 m29.1 m45.2 m

General and administrative expense

4 m6.5 m6.6 m7.1 m8.9 m9 m12.3 m

Operating expense total

16.9 m25.1 m24.1 m30.7 m35 m38.1 m57.5 m

EBIT

(16.9 m)(25.1 m)(24.1 m)(30.7 m)(35 m)(38.1 m)(57.5 m)

Interest expense

21 k41 k

Interest income

21 k41 k

Net Income

(12 m)(21.5 m)(16.9 m)(41.9 m)(65.9 m)(30.5 m)(65.3 m)(103.1 m)(56.8 m)
USDFY, 2014FY, 2015FY, 2016

Cash

127.8 m186.8 m168.5 m

Accounts Receivable

35.6 m

Inventories

1.1 m1.7 m5.1 m

Current Assets

128.8 m188.5 m402.6 m

PP&E

163 k286 k1.4 m

Total Assets

129.7 m189 m404.5 m

Accounts Payable

2.4 m5.2 m12.8 m

Current Liabilities

7.8 m15.3 m35.2 m

Total Liabilities

36 m

Additional Paid-in Capital

188.7 m335 m689 m

Retained Earnings

(66.8 m)(161.3 m)(320.3 m)

Total Equity

121.9 m173.7 m368.5 m

Financial Leverage

1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

49.1 m136.7 m113.2 m224.2 m204.9 m299.7 m189 m320.1 m145.5 m

Current Assets

51.5 m137.8 m114.5 m227.5 m207.5 m302.6 m274.1 m434.7 m349 m

PP&E

69 k134 k269 k285 k249 k865 k959 k1 m1.6 m

Total Assets

51.7 m138 m115.5 m228.5 m208.4 m303.5 m275.6 m436.3 m351.2 m

Accounts Payable

1.9 m2.2 m2.8 m5.2 m3.2 m4.5 m6 m5.2 m8.2 m

Current Liabilities

3.9 m5 m8.9 m11 m10.3 m16 m18.3 m22.3 m31.9 m

Additional Paid-in Capital

187.4 m190.2 m326.2 m330.9 m479.4 m483.8 m678.2 m695.6 m

Retained Earnings

(44.8 m)(54.5 m)(83.7 m)(108.7 m)(132.8 m)(191.9 m)(226.6 m)(264.4 m)(377.1 m)

Total Equity

132.9 m106.5 m217.5 m198.1 m287.5 m257.2 m413.7 m318.4 m

Financial Leverage

1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(33.8 m)(94.5 m)(159 m)

Depreciation and Amortization

51 k115 k281 k

Inventories

(715 k)(681 k)(3.4 m)

Accounts Payable

441 k2.7 m7.8 m

Cash From Operating Activities

119.7 m59 m(118.7 m)

Purchases of PP&E

(128 k)(198 k)(1.4 m)

Cash From Investing Activities

(128 k)(198 k)(230.5 m)

Cash From Financing Activities

146.9 m129.9 m331 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12 m)(21.5 m)(16.9 m)(41.9 m)(65.9 m)(30.5 m)(65.3 m)(103.1 m)(56.8 m)

Depreciation and Amortization

22 k35 k22 k54 k83 k41 k116 k199 k

Accounts Payable

(385 k)(6 k)343 k2.8 m808 k(799 k)941 k116 k8.2 m

Cash From Operating Activities

(10.9 m)(18.4 m)(14.6 m)(33 m)(52.6 m)(27.4 m)(54.1 m)(84.9 m)

Purchases of PP&E

(5 k)(83 k)(110 k)(181 k)(160 k)(341 k)(835 k)(901 k)

Cash From Investing Activities

(5 k)(83 k)(110 k)(181 k)(160 k)(341 k)(84.4 m)(112.1 m)

Cash From Financing Activities

52 m147.1 m112 k129.7 m129.8 m140.7 m140.7 m330.3 m
Y, 2017

Financial Leverage

1.1 x

Sage Therapeutics Market Value History

Traffic Overview of Sage Therapeutics

Sage Therapeutics Online and Social Media Presence

Sage Therapeutics News and Updates

BRIEF-Sage Therapeutics reports positive top-line results

* Sage reports positive top-line results including demonstration of 30-day durability from phase 2 clinical trial of Sage-547 in severe postpartum depression

Sage Therapeutics Company Life and Culture

You may also be interested in